UroGen Pharma Announced Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma Ltd. (NASDAQ:URGN) announced the commencement of a public offering of ordinary shares and pre-funded warrants. The offering is subject to market conditions, and UroGen expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total shares offered. TD Cowen and Guggenheim Securities are joint book-running managers, with Oppenheimer & Co. as lead manager and Ladenburg Thalmann as co-manager.
June 17, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UroGen Pharma Ltd. has announced a public offering of ordinary shares and pre-funded warrants, which may lead to short-term stock price volatility. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares.
The announcement of a public offering typically leads to short-term stock price volatility due to potential dilution of existing shares. The offering's completion and terms are uncertain, adding to the potential impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100